Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
馬薩諸塞州沃特敦，2024年5月8日（GLOBE NEWSWIRE）——Kymera Therapeutics, Inc.（納斯達克股票代碼：KYMR）是一家臨床階段的生物製藥公司，正在開發一種使用靶向蛋白質降解（TPD）的新型小分子藥物，今天宣佈，該公司將參加以下即將舉行的投資者活動的爐邊談話：
- BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; and
- TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m. ET.
- 美國銀行證券2024年醫療保健會議將於太平洋時間5月15日下午 4:20 在內華達州拉斯維加斯舉行；以及
- TD Cowen 5第四 年度腫瘤學創新虛擬峯會將於美國東部時間5月28日下午 1:30 舉行。
Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at . Replays of the webcasts will be archived and available following the events.
演講的網絡直播將在公司網站的 “投資者” 部分的 “新聞與活動” 下提供。網絡廣播的重播將在活動結束後存檔並提供。
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on X (previously Twitter) or LinkedIn.
關於 Kymera Therape
Kymera是一家臨床階段的生物技術公司，在靶向蛋白質降解（TPD）領域處於領先地位，旨在開發能夠解決關鍵健康問題並有可能顯著改善患者生活的藥物。Kymera正在部署TPD，以解決傳統療法無法獲得的疾病靶標和途徑。在將第一款降解劑推廣到免疫疾病臨床後，Kymera專注於提供口服小分子降解劑，爲患有這些疾病的患者提供新一代方便、高效的療法。Kymera還在推進降解腫瘤學項目，這些計劃針對未經藥物或藥物不良的蛋白質，以創造對抗癌症的新方法。Kymera成立於2016年，在過去幾年中一直被公認爲波士頓頂級工作場所之一。如需了解有關我們的科學、研究領域和人員的更多信息，請在 X（前身爲 Twitter）或 LinkedIn 上訪問或關注我們。
Investor and Media Contact:
投資者和媒體聯繫人：
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
賈斯汀·科尼斯伯格
投資者關係副總裁
investors@kymeratx.com
media@kymeratx.com
857-285-5300
譯文內容由第三人軟體翻譯。